Schrodinger (SDGR)
(Delayed Data from NSDQ)
$17.99 USD
+0.40 (2.24%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.00 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.99 USD
+0.40 (2.24%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $18.00 +0.01 (0.06%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth B Momentum F VGM
Zacks News
Omnicell (OMCL) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Omnicell (OMCL) delivered earnings and revenue surprises of 36.59% and 1.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
iRhythm Technologies (IRTC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Compared to Estimates, Schrodinger (SDGR) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
While the top- and bottom-line numbers for Schrodinger (SDGR) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of 12.94% and 17.78%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Omnicell (OMCL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Omnicell (OMCL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Schrodinger (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger (SDGR) delivered earnings and revenue surprises of 0% and 11.24%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 27.27% and 4.73%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Countdown to Schrodinger, Inc. (SDGR) Q4 Earnings: A Look at Estimates Beyond Revenue and EPS
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Schrodinger, Inc. (SDGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.
Compared to Estimates, Schrodinger, Inc. (SDGR) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Schrodinger, Inc. (SDGR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 51.16% and 0.25%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Schrodinger, Inc. (SDGR) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tabula Rasa Healthcare (TRHC) Moves 6.3% Higher: Will This Strength Last?
by Zacks Equity Research
Tabula Rasa Healthcare (TRHC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Schrodinger, Inc. (SDGR) Surges 6.6%: Is This an Indication of Further Gains?
by Zacks Equity Research
Schrodinger, Inc. (SDGR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -127.94% and 3.02%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 22% and 16.74%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
10x Genomics (TXG) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
10x Genomics (TXG) delivered earnings and revenue surprises of 48.28% and 6.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Phreesia (PHR) Soars 6.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Phreesia (PHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Schrodinger, Inc. (SDGR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 8.20% and 14.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -1.64% and 2.88%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Schrodinger, Inc. (SDGR) Q2 Earnings Expected to Decline
by Zacks Equity Research
Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Schrodinger, Inc. (SDGR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of 12.73% and 36.14%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Schrodinger, Inc. (SDGR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Schrodinger, Inc. (SDGR) delivered earnings and revenue surprises of -13.16% and 25.36%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Pulmonx Corporation (LUNG) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Pulmonx Corporation (LUNG) delivered earnings and revenue surprises of 0% and 3.53%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?